No, do not use fosfomycin as prophylaxis after completing Zerbaxa for ESBL UTI
After completing a full 5-day course of Zerbaxa for an ESBL-producing UTI, you should not give a single dose of fosfomycin as prophylaxis at discharge. This approach is not supported by current guidelines or evidence, and fosfomycin is not indicated for prophylaxis in this context.
Why This Is Not Appropriate
Fosfomycin Is Not a Prophylactic Agent
Fosfomycin tromethamine is FDA-approved specifically for treatment of acute uncomplicated cystitis, not for prophylaxis 1. The drug label clearly states it is indicated for uncomplicated UTI treatment in women 18 years and older, administered as a single 3g dose 1. Current guidelines from both JAMA and the European Association of Urology consistently recommend fosfomycin as a treatment option for uncomplicated cystitis, not as prophylaxis 2, 3.
Your Patient Has Already Completed Appropriate Treatment
The FDA-approved duration for Zerbaxa in complicated UTI (cUTI) including pyelonephritis is 7 days 4. However, you mention she completed 5 days. If she has clinically improved and the infection is resolving, adding fosfomycin serves no evidence-based purpose. If she has NOT completed adequate treatment duration, the solution is to extend appropriate therapy, not add prophylaxis.
ESBL UTIs Require Treatment, Not Prophylaxis at Discharge
Recent high-quality evidence demonstrates that fosfomycin can be used as oral transition therapy (not prophylaxis) for ESBL UTIs. A 2026 multicenter RCT showed that oral fosfomycin 3g once daily was noninferior to continued IV therapy when used as step-down treatment after initial IV antibiotics 5. This means fosfomycin could have been used to complete her treatment course, not as a single prophylactic dose after treatment completion.
What You Should Do Instead
If Treatment Is Complete (5 Days Was Adequate)
- Discharge without additional antibiotics if she is clinically improved with resolution of symptoms
- Routine post-treatment urine cultures are not indicated for asymptomatic patients 3
- Counsel on UTI prevention strategies (adequate hydration, post-coital voiding if applicable)
If Treatment Duration Was Inadequate
The standard duration for cUTI with Zerbaxa is 7 days 4. If she needs to complete therapy:
- Switch to oral fosfomycin 3g once daily to complete a total 7-day course (based on 5 showing noninferiority for ESBL UTI transition therapy)
- Alternative: Continue Zerbaxa for 2 more days if IV access remains and oral transition is not feasible
- Ensure susceptibility data supports fosfomycin use (typically >95% susceptibility for E. coli ESBL strains 6, 7)
If She Has Risk Factors for Recurrent UTI
For patients with recurrent UTIs (≥3 UTIs/year or 2 in 6 months), evidence-based prophylaxis strategies include 3:
- Vaginal estrogen in postmenopausal women (strong recommendation)
- Immunoactive prophylaxis (strong recommendation)
- Increased fluid intake
- Probiotics or cranberry products (weak evidence)
- NOT single-dose fosfomycin after completing treatment
Critical Pitfalls to Avoid
- Do not confuse treatment with prophylaxis: Fosfomycin's single-dose regimen is for treating uncomplicated cystitis, not preventing future infections
- Do not underdose: If using fosfomycin to complete treatment, use 3g daily (not a single dose) based on the transition therapy evidence 5
- Verify susceptibility: While ESBL E. coli typically shows 96-100% fosfomycin susceptibility 6, 7, confirm your isolate is susceptible if using it for step-down therapy
- Consider infection severity: The 2026 FOREST trial showed fosfomycin was inferior in MDR bacteremia with urinary source 8, so ensure your patient is hemodynamically stable and non-bacteremic
In summary: Discharge her without additional antibiotics if treatment is complete and she's clinically improved. If you need to extend therapy, use fosfomycin 3g daily (not as a single prophylactic dose) to complete a 7-day total course.